Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

NCT05524935 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.

NCT NCT05524935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05524935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 11, 2022
Completion date
December 31, 2027
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular melanoma, uveal melanoma